Abstract: A genetically modified non-human animal comprising a genome containing an endogenous non-human ACE2 locus genetically modified to encode a complete human ACE2 gene. According to a further embodiment the genome is genetically modified to encode a second, a third, and a fourth complete human ACE2 gene, the human ACE2 gene is at least 85 percent identical to SEQ ID No: 1, the animal of is a mouse, the human ACE2 gene encodes six protein variants, an endogenous Tmprss2 gene is unmodified, a LoxP gene flanks each of a 5? and a 3? end of a nucleic acid sequence of the human ACE2 gene, and the human ACE2 gene is expressed in a lung, kidney, spleen, stomach, liver, intestine, heart, and skeletal muscle of the animal, and a cortex, striatum, middle brain, hippocampus, olfactory bulb, and cerebellum of a brain of the animal.

Abstract: The invention belongs to the field of friction stir welding (FSW) quality prediction and relates to an intelligent prediction method for the tensile strength of FSW joints considering welding temperature and axial force. The invention uses a combination of experiment and theory. FSW experiment is carried out, the infrared thermal imager and force sensor are used to obtain the temperature of the feature points on the advancing side and retreating side of the outside of the shoulder of the weldment surface and the axial force during FSW process. The obtained data is used to train and test the one-dimensional convolutional neural network. The tensile strength prediction of friction stir welding is realized, which provided a reference for welding process control.

Abstract: The present invention belongs to the field of friction stir welding (FSW) temperature detection, and relates to a temperature characterization method of FSW weld zone based on infrared thermal imager. The invention combines theory with experiment. A temperature field simulation model of FSW is established based on DEFORM. The data sets of temperature of surface feature points, the maximum and minimum temperatures in weld zone are obtained according to the simulation model result. Then, Support Vector Regression (SVR) is used to establish a temperature characterization model, which represents the correlation between the temperature of surface feature points and the maximum and minimum temperatures in weld zone. In the actual welding process, an infrared camera is used to measure the temperature of the surface feature point in real-time. Combined with the built temperature characterization model, the characterization of the maximum and minimum temperatures in weld zone is achieved.

Abstract: A method of treating a mammal with one of a central nervous system injury and a neurodegenerative disorder comprising isolating, culturing, and generating neural progenitor cells from a mammalian placenta, and transplanting the placenta derived neural progenitor cells into a brain of the mammal.

Abstract: The present invention belongs to the precise and efficient processing field of micro parts, in particular to a deformation prediction method of micro-milling thin-walled parts. Firstly, based on the finite element simulation software, a finite element simulation model of micro-milling thin-walled parts is established. Johnson-Cook material model and failure criterion are used to describe the material properties and damage criteria of the machined materials, so as to realize the prediction of milling force in the micro-milling process. The accuracy of the model is verified by experiments. Then, based on the birth-death element method, a deformation prediction model of micro-milling thin-walled parts model is established, and the milling force output from the finite element simulation model is loaded into the deformation prediction model. Finally, the deformation prediction of d micro-milling thin-walled parts is realized.

Abstract: The disclosed invention relates to methods and transgenic non-human mammals comprising a full length human VIPR2 genomic region integrated into a genome of the mammal. According to a further embodiment the mammal is a mouse. The disclosed invention further relates to transgenic cells from the transgenic non-human mammal. The disclosed invention further relates to therapeutics and methods of treating Schizophrenia in a human comprising administering a therapeutic, where the therapeutic contains one of a pharmacologically effective amount of a hVIPR2 antagonist, and a CRISPR/Cas9 formulation. The disclosed invention further relates to materials and methods of determining efficacy of an antipsychotic therapeutic in treating a condition comprising administering to the transgenic non-human mammal.

Abstract: A genetically modified non-human animal comprising a genome containing an endogenous non-human ACE2 locus genetically modified to encode a complete human ACE2 gene. According to a further embodiment the genome is genetically modified to encode a second, a third, and a fourth complete human ACE2 gene, the human ACE2 gene is at least 85 percent identical to SEQ ID No: 1, the animal of is a mouse, the human ACE2 gene encodes six protein variants, an endogenous Tmprss2 gene is unmodified, a LoxP gene flanks each of a 5? and a 3? end of a nucleic acid sequence of the human ACE2 gene, and the human ACE2 gene is expressed in a lung, kidney, spleen, stomach, liver, intestine, heart, and skeletal muscle of the animal, and a cortex, striatum, middle brain, hippocampus, olfactory bulb, and cerebellum of a brain of the animal.

Abstract: A method of treating a mammal with one of a central nervous system injury and a neurodegenerative disorder comprising isolating, culturing, and generating neural progenitor cells from a mammalian placenta, and transplanting the placenta derived neural progenitor cells into a brain of the mammal.

Abstract: Embodiments of the present invention disclose a power control method and apparatus, relate to the field of wireless communications, and are invented for reducing power pressure of an air interface of a base station and ensuring a stable network environment. The method includes: determining whether received total wideband power (RTWP) of an air interface exceeds a set first congestion threshold value; when the RTWP of the air interface exceeds the set first congestion threshold value, sending a congestion indication to a radio network controller (RNC), where the congestion indication is used for indicating that the RNC is forbidden from up-regulating a target signal-to-interference ratio (SIR); receiving a target SIR sent by the RNC; down-regulating the target SIR sent by the RNC; and notifying, based on the down-regulated target SIR, a user equipment (UE) to reduce transmit power. The present invention is mainly applied to the field of power control.

Abstract: Embodiments of the present invention disclose a power control method and apparatus, relate to the field of wireless communications, and are invented for reducing power pressure of an air interface of a base station and ensuring a stable network environment. The method includes: determining whether received total wideband power (RTWP) of an air interface exceeds a set first congestion threshold value; when the RTWP of the air interface exceeds the set first congestion threshold value, sending a congestion indication to a radio network controller (RNC), where the congestion indication is used for indicating that the RNC is forbidden from up-regulating a target signal-to-interference ratio (SIR); receiving a target SIR sent by the RNC; down-regulating the target SIR sent by the RNC; and notifying, based on the down-regulated target SIR, a user equipment (UE) to reduce transmit power. The present invention is mainly applied to the field of power control.

Abstract: A composition comprising mithramycin or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of renal cell carcinoma. In particular, the composition is suitable for use in the treatment of clear cell renal cell carcinoma. The composition is particularly useful for use in the treatment of renal cell carcinoma associated with Von Hippel-Lindau disease or Birt-Hogg-Dubé syndrome. A composition comprising mithramycin or a pharmaceutically acceptable salt or solvate thereof for use as a cytotoxic agent against FLCN-null or VHL-null renal cell carcinoma cells.

Abstract: An apparatus and a computational method are provided for localizing a positron-emitting source during an intervention using positron emission tomography (PET) imaging. The apparatus is designed to accelerate the image acquisition and reconstruction process such that the resulting image presentation can be used to quickly reposition an interventional device in relation to a lesion. By limiting the processing of data in the acquisition to a focal plane which extends through the localization target, and which is oriented to capture and display motion during the intervention, and then by displaying a persistence image which is frequently refreshed, a user can visualize movement of the positron-emitting source for optimizing the position of the interventional device. The positron-emitting source(s) can be radiolabeled tissue, a radiolabeled interventional device, a radiolabeled fiducial, or any combination thereof.